Loading…
Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration
We have investigated the detection, confirmation, and metabolism of the beta-adrenergic agonist ractopamine administered as Paylean to the horse. A Testing Components Corporation enzyme-linked imunosorbent assay (ELISA) kit for ractopamine displayed linear response between 1.0 and 100 ng/mL with an...
Saved in:
Published in: | Journal of analytical toxicology 2004-05, Vol.28 (4), p.226-237 |
---|---|
Main Authors: | , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c425t-afbc9685d48592d6262ea0e00bc3c298912de4b73a0b6940a35fa57658db3b553 |
---|---|
cites | |
container_end_page | 237 |
container_issue | 4 |
container_start_page | 226 |
container_title | Journal of analytical toxicology |
container_volume | 28 |
creator | Lehner, A.F. Hughes, C.G. Harkins, J.D. Nickerson, C. Mollett, B. Dirikolu, L. Bosken, J. Camargo, F. Boyles, J. Troppmann, A. Karpiesiuk, W. Woods, W.E. Tobin, T. |
description | We have investigated the detection, confirmation, and metabolism of the beta-adrenergic agonist ractopamine administered as Paylean to the horse. A Testing Components Corporation enzyme-linked imunosorbent assay (ELISA) kit for ractopamine displayed linear response between 1.0 and 100 ng/mL with an I-50 of 10 ng/mL and an effective screening limit of detection of 50 ng/mL. The kit was readily able to detect ractopamine equivalents in unhydrolyzed urine up to 24 h following a 300-mg oral dose. Gas chromatography-mass spectrometry (GC-MS) confirmation comprised glucuronidase treatment, solid-phase extraction, and trimethylsilyl derivatization, with selected-ion monitoring of ractopamine-tris (trimethylsilane) (TMS) m/z 267, 250, 179, and 502 ions. Quantitation was elaborated in comparison to a 445 Mw isoxsuprine-bis (TMS) internal standard monitored simultaneously. The instrumental limit of detection, defined as that number of ng on column for which signal-to-noise ratios for one or more diagnostic ions fell below a value of three, was 0.1 ng, corresponding to roughly 5 ng/mL in matrix. Based on the quantitation ions for ractopamine standards extracted from urine, standard curves showed a linear response for ractopamine concentrations between 10 and 100 ng/mL with a correlation coefficient r > 0.99, whereas standards in the concentration range of 10–1000 ng/mL were fit to a second-order regression curve with r > 0.99. The lower limit of detection for ractopamine in urine, defined as the lowest concentration at which the identity of ractopamine could be confirmed by comparison of diagnostic MS ion ratios, ranged between 25 and 50 ng/mL. Urine concentration of parent ractopamine 24 h post-dose was measured at 360 ng/mL by GC-MS after oral administration of 300 rag. Urinary metabolites were identified by electrospray ionization (+) tandem quadrupole mass spectrometry and were shown to include glucuronide, methyl, and mixed methyl-glucuronide conjugates. We also considered the possibility that an unusual conjugate added 113 amu to give an observed m/z 415 [M+H] species or two times 113 amu to give an m/z 528 [M+H] species with a daughter ion mass spectrum related to the previous one. Sulfate and mixed methyl-sulfate conjugates were revealed following glucuronidase treatment, suggesting that sulfation occurs in combination with glucuronidation. We noted a paired chromatographic peak phenomenon of apparent ractopamine metabolites appearing as doublets of equivalen |
doi_str_mv | 10.1093/jat/28.4.226 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72009518</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jat/28.4.226</oup_id><sourcerecordid>72009518</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-afbc9685d48592d6262ea0e00bc3c298912de4b73a0b6940a35fa57658db3b553</originalsourceid><addsrcrecordid>eNqF0E1rFDEYwPEgit1Wb55lLtpLZ5v3TI7raruFiiItSC_hmUwG0s5MtkkW7JfyQ_jJTHcX7a2nQPJ7nsAfoXcEzwnW7PQW8ilt5nxOqXyBZkRzUVOO2Us0w4TLmiuJD9BhSrcYE9lI9hodEEEaLRWdobvPLjubfZgqmLpqGabexxG2F6GvfoDNYQ2jn9z2_SKn6qvL0IbBZ5cqP1WrEJOrruMjWfTZxeo7PAwOpj-_q0VXJn3KcbvwDXrVw5Dc2_15hK7PvlwtV_Xlt_OL5eKytpyKXEPfWi0b0fFGaNpJKqkD7DBuLbNUN5rQzvFWMcCt1BwDEz0IJUXTtawVgh2hj7u96xjuNy5lM_pk3TDA5MImGUUx1qVAgSc7aGNIKbrerKMfIT4Ygs1jXFPiGtoYbkrcwt_v927a0XX_8b5mAR_2AJKFoY8wWZ-eOEUoIaq4450Lm_VzX9Y7WSK6X_8sxDsjFVPCrH7emBX7dHXW3Eij2F9XF58l</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72009518</pqid></control><display><type>article</type><title>Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration</title><source>Oxford Journals Online</source><source>Alma/SFX Local Collection</source><creator>Lehner, A.F. ; Hughes, C.G. ; Harkins, J.D. ; Nickerson, C. ; Mollett, B. ; Dirikolu, L. ; Bosken, J. ; Camargo, F. ; Boyles, J. ; Troppmann, A. ; Karpiesiuk, W. ; Woods, W.E. ; Tobin, T.</creator><creatorcontrib>Lehner, A.F. ; Hughes, C.G. ; Harkins, J.D. ; Nickerson, C. ; Mollett, B. ; Dirikolu, L. ; Bosken, J. ; Camargo, F. ; Boyles, J. ; Troppmann, A. ; Karpiesiuk, W. ; Woods, W.E. ; Tobin, T.</creatorcontrib><description>We have investigated the detection, confirmation, and metabolism of the beta-adrenergic agonist ractopamine administered as Paylean to the horse. A Testing Components Corporation enzyme-linked imunosorbent assay (ELISA) kit for ractopamine displayed linear response between 1.0 and 100 ng/mL with an I-50 of 10 ng/mL and an effective screening limit of detection of 50 ng/mL. The kit was readily able to detect ractopamine equivalents in unhydrolyzed urine up to 24 h following a 300-mg oral dose. Gas chromatography-mass spectrometry (GC-MS) confirmation comprised glucuronidase treatment, solid-phase extraction, and trimethylsilyl derivatization, with selected-ion monitoring of ractopamine-tris (trimethylsilane) (TMS) m/z 267, 250, 179, and 502 ions. Quantitation was elaborated in comparison to a 445 Mw isoxsuprine-bis (TMS) internal standard monitored simultaneously. The instrumental limit of detection, defined as that number of ng on column for which signal-to-noise ratios for one or more diagnostic ions fell below a value of three, was 0.1 ng, corresponding to roughly 5 ng/mL in matrix. Based on the quantitation ions for ractopamine standards extracted from urine, standard curves showed a linear response for ractopamine concentrations between 10 and 100 ng/mL with a correlation coefficient r > 0.99, whereas standards in the concentration range of 10–1000 ng/mL were fit to a second-order regression curve with r > 0.99. The lower limit of detection for ractopamine in urine, defined as the lowest concentration at which the identity of ractopamine could be confirmed by comparison of diagnostic MS ion ratios, ranged between 25 and 50 ng/mL. Urine concentration of parent ractopamine 24 h post-dose was measured at 360 ng/mL by GC-MS after oral administration of 300 rag. Urinary metabolites were identified by electrospray ionization (+) tandem quadrupole mass spectrometry and were shown to include glucuronide, methyl, and mixed methyl-glucuronide conjugates. We also considered the possibility that an unusual conjugate added 113 amu to give an observed m/z 415 [M+H] species or two times 113 amu to give an m/z 528 [M+H] species with a daughter ion mass spectrum related to the previous one. Sulfate and mixed methyl-sulfate conjugates were revealed following glucuronidase treatment, suggesting that sulfation occurs in combination with glucuronidation. We noted a paired chromatographic peak phenomenon of apparent ractopamine metabolites appearing as doublets of equivalent intensity with nearly identical mass spectra on GC-MS and concluded that this phenomenon is consistent with Paylean being a mixture of RR, RS, SR, and SS diastereomers of ractopamine. The results suggest that ELISA-based screening followed by glucuronide hydrolysis, parent drug recovery, and TMS derivatization provide an effective pathway for detection and GC-MS confirmation of ractopamine in equine urine.</description><identifier>ISSN: 0146-4760</identifier><identifier>EISSN: 1945-2403</identifier><identifier>DOI: 10.1093/jat/28.4.226</identifier><identifier>PMID: 15189672</identifier><identifier>CODEN: JATOD3</identifier><language>eng</language><publisher>Niles, IL: Oxford University Press</publisher><subject>Analysis ; Animals ; Biological and medical sciences ; Enzyme-Linked Immunosorbent Assay ; Female ; Gas Chromatography-Mass Spectrometry ; General pharmacology ; Growth Substances - metabolism ; Growth Substances - urine ; Horses - urine ; Medical sciences ; Pharmacology. Drug treatments ; Phenethylamines - metabolism ; Phenethylamines - urine ; Reference Standards ; Reproducibility of Results ; Sensitivity and Specificity ; Spectrometry, Mass, Electrospray Ionization ; Substance Abuse Detection - veterinary ; Urinalysis - veterinary</subject><ispartof>Journal of analytical toxicology, 2004-05, Vol.28 (4), p.226-237</ispartof><rights>2004</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-afbc9685d48592d6262ea0e00bc3c298912de4b73a0b6940a35fa57658db3b553</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15712117$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15189672$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lehner, A.F.</creatorcontrib><creatorcontrib>Hughes, C.G.</creatorcontrib><creatorcontrib>Harkins, J.D.</creatorcontrib><creatorcontrib>Nickerson, C.</creatorcontrib><creatorcontrib>Mollett, B.</creatorcontrib><creatorcontrib>Dirikolu, L.</creatorcontrib><creatorcontrib>Bosken, J.</creatorcontrib><creatorcontrib>Camargo, F.</creatorcontrib><creatorcontrib>Boyles, J.</creatorcontrib><creatorcontrib>Troppmann, A.</creatorcontrib><creatorcontrib>Karpiesiuk, W.</creatorcontrib><creatorcontrib>Woods, W.E.</creatorcontrib><creatorcontrib>Tobin, T.</creatorcontrib><title>Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration</title><title>Journal of analytical toxicology</title><addtitle>Journal of Analytical Toxicology</addtitle><addtitle>Journal of Analytical Toxicology</addtitle><description>We have investigated the detection, confirmation, and metabolism of the beta-adrenergic agonist ractopamine administered as Paylean to the horse. A Testing Components Corporation enzyme-linked imunosorbent assay (ELISA) kit for ractopamine displayed linear response between 1.0 and 100 ng/mL with an I-50 of 10 ng/mL and an effective screening limit of detection of 50 ng/mL. The kit was readily able to detect ractopamine equivalents in unhydrolyzed urine up to 24 h following a 300-mg oral dose. Gas chromatography-mass spectrometry (GC-MS) confirmation comprised glucuronidase treatment, solid-phase extraction, and trimethylsilyl derivatization, with selected-ion monitoring of ractopamine-tris (trimethylsilane) (TMS) m/z 267, 250, 179, and 502 ions. Quantitation was elaborated in comparison to a 445 Mw isoxsuprine-bis (TMS) internal standard monitored simultaneously. The instrumental limit of detection, defined as that number of ng on column for which signal-to-noise ratios for one or more diagnostic ions fell below a value of three, was 0.1 ng, corresponding to roughly 5 ng/mL in matrix. Based on the quantitation ions for ractopamine standards extracted from urine, standard curves showed a linear response for ractopamine concentrations between 10 and 100 ng/mL with a correlation coefficient r > 0.99, whereas standards in the concentration range of 10–1000 ng/mL were fit to a second-order regression curve with r > 0.99. The lower limit of detection for ractopamine in urine, defined as the lowest concentration at which the identity of ractopamine could be confirmed by comparison of diagnostic MS ion ratios, ranged between 25 and 50 ng/mL. Urine concentration of parent ractopamine 24 h post-dose was measured at 360 ng/mL by GC-MS after oral administration of 300 rag. Urinary metabolites were identified by electrospray ionization (+) tandem quadrupole mass spectrometry and were shown to include glucuronide, methyl, and mixed methyl-glucuronide conjugates. We also considered the possibility that an unusual conjugate added 113 amu to give an observed m/z 415 [M+H] species or two times 113 amu to give an m/z 528 [M+H] species with a daughter ion mass spectrum related to the previous one. Sulfate and mixed methyl-sulfate conjugates were revealed following glucuronidase treatment, suggesting that sulfation occurs in combination with glucuronidation. We noted a paired chromatographic peak phenomenon of apparent ractopamine metabolites appearing as doublets of equivalent intensity with nearly identical mass spectra on GC-MS and concluded that this phenomenon is consistent with Paylean being a mixture of RR, RS, SR, and SS diastereomers of ractopamine. The results suggest that ELISA-based screening followed by glucuronide hydrolysis, parent drug recovery, and TMS derivatization provide an effective pathway for detection and GC-MS confirmation of ractopamine in equine urine.</description><subject>Analysis</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Female</subject><subject>Gas Chromatography-Mass Spectrometry</subject><subject>General pharmacology</subject><subject>Growth Substances - metabolism</subject><subject>Growth Substances - urine</subject><subject>Horses - urine</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenethylamines - metabolism</subject><subject>Phenethylamines - urine</subject><subject>Reference Standards</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Spectrometry, Mass, Electrospray Ionization</subject><subject>Substance Abuse Detection - veterinary</subject><subject>Urinalysis - veterinary</subject><issn>0146-4760</issn><issn>1945-2403</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqF0E1rFDEYwPEgit1Wb55lLtpLZ5v3TI7raruFiiItSC_hmUwG0s5MtkkW7JfyQ_jJTHcX7a2nQPJ7nsAfoXcEzwnW7PQW8ilt5nxOqXyBZkRzUVOO2Us0w4TLmiuJD9BhSrcYE9lI9hodEEEaLRWdobvPLjubfZgqmLpqGabexxG2F6GvfoDNYQ2jn9z2_SKn6qvL0IbBZ5cqP1WrEJOrruMjWfTZxeo7PAwOpj-_q0VXJn3KcbvwDXrVw5Dc2_15hK7PvlwtV_Xlt_OL5eKytpyKXEPfWi0b0fFGaNpJKqkD7DBuLbNUN5rQzvFWMcCt1BwDEz0IJUXTtawVgh2hj7u96xjuNy5lM_pk3TDA5MImGUUx1qVAgSc7aGNIKbrerKMfIT4Ygs1jXFPiGtoYbkrcwt_v927a0XX_8b5mAR_2AJKFoY8wWZ-eOEUoIaq4450Lm_VzX9Y7WSK6X_8sxDsjFVPCrH7emBX7dHXW3Eij2F9XF58l</recordid><startdate>20040501</startdate><enddate>20040501</enddate><creator>Lehner, A.F.</creator><creator>Hughes, C.G.</creator><creator>Harkins, J.D.</creator><creator>Nickerson, C.</creator><creator>Mollett, B.</creator><creator>Dirikolu, L.</creator><creator>Bosken, J.</creator><creator>Camargo, F.</creator><creator>Boyles, J.</creator><creator>Troppmann, A.</creator><creator>Karpiesiuk, W.</creator><creator>Woods, W.E.</creator><creator>Tobin, T.</creator><general>Oxford University Press</general><general>Preston</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20040501</creationdate><title>Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration</title><author>Lehner, A.F. ; Hughes, C.G. ; Harkins, J.D. ; Nickerson, C. ; Mollett, B. ; Dirikolu, L. ; Bosken, J. ; Camargo, F. ; Boyles, J. ; Troppmann, A. ; Karpiesiuk, W. ; Woods, W.E. ; Tobin, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-afbc9685d48592d6262ea0e00bc3c298912de4b73a0b6940a35fa57658db3b553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Analysis</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Female</topic><topic>Gas Chromatography-Mass Spectrometry</topic><topic>General pharmacology</topic><topic>Growth Substances - metabolism</topic><topic>Growth Substances - urine</topic><topic>Horses - urine</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenethylamines - metabolism</topic><topic>Phenethylamines - urine</topic><topic>Reference Standards</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Spectrometry, Mass, Electrospray Ionization</topic><topic>Substance Abuse Detection - veterinary</topic><topic>Urinalysis - veterinary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lehner, A.F.</creatorcontrib><creatorcontrib>Hughes, C.G.</creatorcontrib><creatorcontrib>Harkins, J.D.</creatorcontrib><creatorcontrib>Nickerson, C.</creatorcontrib><creatorcontrib>Mollett, B.</creatorcontrib><creatorcontrib>Dirikolu, L.</creatorcontrib><creatorcontrib>Bosken, J.</creatorcontrib><creatorcontrib>Camargo, F.</creatorcontrib><creatorcontrib>Boyles, J.</creatorcontrib><creatorcontrib>Troppmann, A.</creatorcontrib><creatorcontrib>Karpiesiuk, W.</creatorcontrib><creatorcontrib>Woods, W.E.</creatorcontrib><creatorcontrib>Tobin, T.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of analytical toxicology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lehner, A.F.</au><au>Hughes, C.G.</au><au>Harkins, J.D.</au><au>Nickerson, C.</au><au>Mollett, B.</au><au>Dirikolu, L.</au><au>Bosken, J.</au><au>Camargo, F.</au><au>Boyles, J.</au><au>Troppmann, A.</au><au>Karpiesiuk, W.</au><au>Woods, W.E.</au><au>Tobin, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration</atitle><jtitle>Journal of analytical toxicology</jtitle><stitle>Journal of Analytical Toxicology</stitle><addtitle>Journal of Analytical Toxicology</addtitle><date>2004-05-01</date><risdate>2004</risdate><volume>28</volume><issue>4</issue><spage>226</spage><epage>237</epage><pages>226-237</pages><issn>0146-4760</issn><eissn>1945-2403</eissn><coden>JATOD3</coden><abstract>We have investigated the detection, confirmation, and metabolism of the beta-adrenergic agonist ractopamine administered as Paylean to the horse. A Testing Components Corporation enzyme-linked imunosorbent assay (ELISA) kit for ractopamine displayed linear response between 1.0 and 100 ng/mL with an I-50 of 10 ng/mL and an effective screening limit of detection of 50 ng/mL. The kit was readily able to detect ractopamine equivalents in unhydrolyzed urine up to 24 h following a 300-mg oral dose. Gas chromatography-mass spectrometry (GC-MS) confirmation comprised glucuronidase treatment, solid-phase extraction, and trimethylsilyl derivatization, with selected-ion monitoring of ractopamine-tris (trimethylsilane) (TMS) m/z 267, 250, 179, and 502 ions. Quantitation was elaborated in comparison to a 445 Mw isoxsuprine-bis (TMS) internal standard monitored simultaneously. The instrumental limit of detection, defined as that number of ng on column for which signal-to-noise ratios for one or more diagnostic ions fell below a value of three, was 0.1 ng, corresponding to roughly 5 ng/mL in matrix. Based on the quantitation ions for ractopamine standards extracted from urine, standard curves showed a linear response for ractopamine concentrations between 10 and 100 ng/mL with a correlation coefficient r > 0.99, whereas standards in the concentration range of 10–1000 ng/mL were fit to a second-order regression curve with r > 0.99. The lower limit of detection for ractopamine in urine, defined as the lowest concentration at which the identity of ractopamine could be confirmed by comparison of diagnostic MS ion ratios, ranged between 25 and 50 ng/mL. Urine concentration of parent ractopamine 24 h post-dose was measured at 360 ng/mL by GC-MS after oral administration of 300 rag. Urinary metabolites were identified by electrospray ionization (+) tandem quadrupole mass spectrometry and were shown to include glucuronide, methyl, and mixed methyl-glucuronide conjugates. We also considered the possibility that an unusual conjugate added 113 amu to give an observed m/z 415 [M+H] species or two times 113 amu to give an m/z 528 [M+H] species with a daughter ion mass spectrum related to the previous one. Sulfate and mixed methyl-sulfate conjugates were revealed following glucuronidase treatment, suggesting that sulfation occurs in combination with glucuronidation. We noted a paired chromatographic peak phenomenon of apparent ractopamine metabolites appearing as doublets of equivalent intensity with nearly identical mass spectra on GC-MS and concluded that this phenomenon is consistent with Paylean being a mixture of RR, RS, SR, and SS diastereomers of ractopamine. The results suggest that ELISA-based screening followed by glucuronide hydrolysis, parent drug recovery, and TMS derivatization provide an effective pathway for detection and GC-MS confirmation of ractopamine in equine urine.</abstract><cop>Niles, IL</cop><pub>Oxford University Press</pub><pmid>15189672</pmid><doi>10.1093/jat/28.4.226</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0146-4760 |
ispartof | Journal of analytical toxicology, 2004-05, Vol.28 (4), p.226-237 |
issn | 0146-4760 1945-2403 |
language | eng |
recordid | cdi_proquest_miscellaneous_72009518 |
source | Oxford Journals Online; Alma/SFX Local Collection |
subjects | Analysis Animals Biological and medical sciences Enzyme-Linked Immunosorbent Assay Female Gas Chromatography-Mass Spectrometry General pharmacology Growth Substances - metabolism Growth Substances - urine Horses - urine Medical sciences Pharmacology. Drug treatments Phenethylamines - metabolism Phenethylamines - urine Reference Standards Reproducibility of Results Sensitivity and Specificity Spectrometry, Mass, Electrospray Ionization Substance Abuse Detection - veterinary Urinalysis - veterinary |
title | Detection and Confirmation of Ractopamine and Its Metabolites in Horse Urine After Paylean® Administration |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T08%3A41%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20and%20Confirmation%20of%20Ractopamine%20and%20Its%20Metabolites%20in%20Horse%20Urine%20After%20Paylean%C2%AE%20Administration&rft.jtitle=Journal%20of%20analytical%20toxicology&rft.au=Lehner,%20A.F.&rft.date=2004-05-01&rft.volume=28&rft.issue=4&rft.spage=226&rft.epage=237&rft.pages=226-237&rft.issn=0146-4760&rft.eissn=1945-2403&rft.coden=JATOD3&rft_id=info:doi/10.1093/jat/28.4.226&rft_dat=%3Cproquest_cross%3E72009518%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c425t-afbc9685d48592d6262ea0e00bc3c298912de4b73a0b6940a35fa57658db3b553%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72009518&rft_id=info:pmid/15189672&rft_oup_id=10.1093/jat/28.4.226&rfr_iscdi=true |